Author Archives: Guest Blogger

So Who’s in Charge of Medicines in Brussels?

So now we know who is to do what on health issues in the new European Commission. Or do we? The furor that the new boss of the commission, Jean-Claude Juncker, unleashed with the plans for his new team, weeks before it took office, is still reverberating around Brussels. Peter O’ Donnell reports on the […]
Posted in Europe, Guest Blog, Op-Ed, Regulatory | Tagged , , , , , | Leave a comment

Amgen and Sandoz in Legal Battle Over Biosimilar Application

By Randi Hernandez In a landmark lawsuit over the first biosimilar application, Amgen is suing Sandoz for unlawfully refusing to follow the patent resolution protocol laid out by the rules of the Biologics Price Competition and Innovation Act of 2009 (BPCIA).
Posted in Biotech, FDA, Legal | Tagged , , , , | Leave a comment

The Pharma Leadership Challenge: Thawing the “Frozen” Middle Managers

The challenge for senior leadership is to enable the layers of middle management to work to their full potential. Mike Straw argues that ‘failing fast’ should become the new mantra if pharma is going to drive greater innovation and creativity. J. Michael Pearson, CEO of Valeant, the Canadian based speciality drugmaker, recently said that “the […]
Posted in Guest Blog, leadership, Strategy | Tagged , , | 1 Comment

New Scottish Medicines Fund Boosted by UK PPRS

 The 2014 Pharmaceutical Price Regulation Scheme (PPRS), the voluntary agreement to cover pricing of branded medicines supplied to the NHS in the UK, included provisions for member companies to pay back to the Department of Health (DH) if spend went over pre-agreed growth rates.  That has translated into £150 million already for the first two […]
Posted in Europe | Tagged , , , , | Leave a comment

Is Pfizer Ready for Another Acquisition?

After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover? This Applied Clinical Trials article discusses some background on Pfizer’s financial history, evaluates its R&D portfolio, and determines whether it is ready for another acquisition attempt. Read more…
Posted in Deals, Strategy | Tagged , , | Leave a comment
  • Categories

  • Meta